November 16, 2006 – High levels of the biggest selling biotech drugs caused a 34% increase in heart problems, according to a study published today in The New England Journal of Medicine. The drugs treat anemia, caused either by chemotherapy or kidney failure, and they are very familiar names: Epogen and Aranesp from Amgen, and Procrit from Johnson & Johnson. There is no question about the value of the drugs, but the study questions the level at which they are prescribed. More details...
